Liability Related to the Revenue Participation Right (Details) - USD ($) |
1 Months Ended | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|---|
Mar. 31, 2026 |
Jun. 30, 2026 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Dec. 31, 2025 |
|
| Other Commitments [Line Items] | |||||
| Non-cash interest expense related to revenue participation right liability | $ 5,941,000 | $ 0 | |||
| Royalty Pharma | Royalty Agreement | |||||
| Other Commitments [Line Items] | |||||
| Authorized funding | $ 275,000,000.0 | ||||
| Royalty rate | 9.25% | ||||
| Proceeds received | $ 200,000,000.0 | ||||
| Additional payment | $ 75,000,000.0 | ||||
| Initial investment proceeds multiple, maximum | 3.0 | ||||
| Initial investment proceeds multiple, minimum | 2.5 | ||||
| Transaction costs | $ 400,000 | ||||
| Annual interest rate | 12.00% | 12.00% | |||
| Non-cash interest expense related to revenue participation right liability | $ 5,900,000 | ||||
| Payments for royalties | $ 0 | $ 0 | |||